Waltz Laboratory

Peer Reviewed Publications

2024

Davis, James C; Waltz, Susan E 2024. The MET Family of Receptor Tyrosine Kinases Promotes a Shift to Pro-Tumor Metabolism. Genes, 15 7,

Hazra, Aditi; Goldstein, Karen M; Waltz, Susan E; Chiba, Akiko; Colonna, Sarah V; Kelley, Michael J; Moss, Haley A; Zullig, Leah L 2024. Summary and Roadmap of Breast Cancer Research in the Veterans Affairs. Military medicine, ,

Korns, Julianna; Wicker, Christina A; Lehn, Maria; Shyamsunder, Shreya; Thompson, Samuel; Lester, Carissa; Wise-Draper, Trisha M; Waltz, Susan E; Takiar, Vinita 2024. Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinoma. Cancer letters, , 217320

Vicente-Muñoz, Sara; Davis, James C; Lane, Adam; Lane, Andrew N; Waltz, Susan E; Wells, Susanne I 2024. Lipid profiling of RON and DEK-dependent signaling in breast cancer guides discovery of gene networks predictive of poor outcomes. Frontiers in oncology, 14 , 1382986

2023

Hunt, Brian G; Fox, Levi H; Davis, James C; Jones, Angelle; Lu, Zhixin; Waltz, Susan E 2023. An Introduction and Overview of RON Receptor Tyrosine Kinase Signaling. Genes, 14 2,

Oropeza, Elena; Seker, Sinem; Carrel, Sabrina; Mazumder, Aloran; Lozano, Daniel; Jimenez, Athena; VandenHeuvel, Sabrina N; Noltensmeyer, Dillon A; Punturi, Nindo B; Lei, Jonathan T; Lim, Bora; Waltz, Susan E; Raghavan, Shreya A; Bainbridge, Matthew N; Haricharan, Svasti 2023. Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness. Science advances, 9 26, eadf2860

Hunt, Brian G; Davis, James C; Fox, Levi H; Vicente-Muñoz, Sara; Lester, Carissa; Wells, Susanne I; Waltz, Susan E 2023. RON-augmented cholesterol biosynthesis in breast cancer metastatic progression and recurrence. Oncogene, 42 21, 1716-1727

2022

Ruiz-Torres, Sasha J; Bourn, Jennifer R; Benight, Nancy M; Hunt, Brian G; Lester, Carissa; Waltz, Susan E 2022. Macrophage-mediated RON signaling supports breast cancer growth and progression through modulation of IL-35. Oncogene, 41(3) Jan, 321-333

Hunt, Brian G; Jones, Angelle; Lester, Carissa; Davis, James C; Benight, Nancy M; Waltz, Susan E 2022. RON (MST1R) and HGFL (MST1) Co-Overexpression Supports Breast Tumorigenesis through Autocrine and Paracrine Cellular Crosstalk. Cancers, 14 10,

Brown, Nicholas E; Jones, Angelle; Hunt, Brian G; Waltz, Susan E 2022. Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling. The Prostate, ,

Vicente-Muñoz, Sara; Hunt, Brian G; Lange, Taylor E; Wells, Susanne I; Waltz, Susan E 2022. NMR-based metabolomic analysis identifies RON-DEK-?-catenin dependent metabolic pathways and a gene signature that stratifies breast cancer patient survival. PloS one, 17 9, e0274128

2021

Bourn, Jennifer R; Ruiz-Torres, Sasha J; Hunt, Brian G; Benight, Nancy M; Waltz, Susan E 2021. Tumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling. Cancer letters, 503 , 75-90

Wicker, Christina A; Hunt, Brian G; Krishnan, Sunil; Aziz, Kathryn; Parajuli, Shobha; Palackdharry, Sarah; Elaban, William R; Wise-Draper, Trisha M; Mills, Gordon B; Waltz, Susan E; Takiar, Vinita 2021. Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models. Cancer letters, 502 , 180-188